Optimized Predictive Treatment In Medications for Unipolar Major Depression (OPTIMUM-D)
Major Depressive DisorderThis is a study that will test a predictive biomarker algorithm based on results from a previous study. The goal of this study is to integrate clinical, imaging, EEG, and molecular data across 8 sites to predict treatment outcome for patients experiencing a major depressive episode (MDE).
null
Participation Requirements
-
Sex:
ALL -
Eligible Ages:
18 to 65
Participation Criteria
Patients
Inclusion Criteria:
* Outpatients 18 to 65 years of age.
* Meet DSM-5 criteria for MDE in MDD as determined by SCID-5.
* Free of psychotropic medications for at least 5 half-lives (e.g. 1 week for most antidepressants, 5 weeks for fluoxetine) before baseline Visit 1 (exceptions: stable use of hypnotics; stable use of stimulants for attention-deficit/hyperactive disorder).
* MADRS score ≥ 24.
* Fluency in English, sufficient to complete the interviews and self-report questionnaires.
Exclusion Criteria:
* Any diagnosis, other than MDD, that is considered the primary diagnosis.
* Bipolar I or Bipolar-II diagnosis.
* Presence of a significant Axis II diagnosis (borderline, antisocial).
* High suicidal risk, defined by clinician judgment.
* Substance dependence/abuse in the past 6 months.
* Presence of significant neurological disorders, head trauma, or other unstable medical conditions.
* Pregnant or breastfeeding.
* Failure of 4 or more adequate pharmacologic interventions (as determined by the Antidepressant Treatment History Form).
* Started psychological treatment within the past 3 months with the intent of continuing treatment.
* Patients who have previously failed escitalopram or showed intolerance to escitalopram or brexpiprazole, and patients at risk for hypomanic switch (i.e. with a history of antidepressant induced hypomania).
Healthy Comparison (HC) Participants
Inclusion Criteria:
* 18 to 65 years of age.
* No history of psychiatric disorders (as determined by SCID-5) or significant physical conditions (e.g. arthritis, fibromyalgia).
* Fluency in English, sufficient to complete the interviews and self-report questionnaires.
Study Location
McMaster University
McMaster UniversityHamilton, Ontario
Canada
Contact Study Team
Nova Scotia Health Authority
Nova Scotia Health AuthorityHalifax, Nova Scotia
Canada
Contact Study Team
Centre for Addiction and Mental Health
Centre for Addiction and Mental HealthToronto, Ontario
Canada
Contact Study Team
University of Calgary
University of CalgaryCalgary, Alberta
Canada
Contact Study Team
Queen's University
Queen's UniversityKingston, Ontario
Canada
Contact Study Team
University of British Columbia
University of British ColumbiaVancouver, British Columbia
Canada
Contact Study Team
University Health Network
University Health NetworkToronto, Ontario
Canada
Contact Study Team
- Study Sponsored By
- Nova Scotia Health Authority
- Participants Required
- More Information
- Study ID:
NCT05017311